Aradigm Starts Cystic Fibrosis Study

Aradigm has begun a Phase II study of its proprietary inhaled liposomal formulation of ciprofloxacin in patients with cystic fibrosis.

The multicenter trial will study 24 adult cystic fibrosis patients in Australia and New Zealand. Following an antibiotic washout period, patients will receive ciprofloxacin for a period of 14 consecutive days.

Primary efficacy will be based on the change in the density of pseudomonas aeruginosa bacterial colony-forming units in sputum between pre- and post-dosing levels. Additional efficacy endpoints will include pulmonary function measurements and respiratory symptoms, Aradigm said.